PD1 and PDL1 inhibitors (in short, PDx) have revolutionized cancer care since the approval of pembrolizumab for melanoma in 2014. Since then, the field has expanded both in terms of the number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results